Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.27 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in renal collecting duct intercalated cells | 0.75 |
| chemistry Open Targets | compounds already reach it: tarenflurbil, nirogacestat hydrobromide, avagacestat +4 | 0.90 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 56 Parkinson's papers of 749 | 0.47 |
| pathways Reactome | 12 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 1476
Sealed predictions
- PSEN2 in dopamine neurons, braak+0.03 (p 0.946) → -0.54 (p 0.136)receipt 1483
Swarm cases
receipt 1483: PSEN2 in dopamine neurons, braak
- power
- full sample -0.24 (p 0.346, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.225, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.111, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.14, sign flips 0; without severely affected donors -0.24 (p 0.346, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PSEN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts